I work here
eskalith cr 450 On December 13, 2012, the Company announced positive data on an endpointexamining initial percentage tumour changes between the pre-treatmentand first post-treatment scans (typically performed at six weekspost-first treatment) of all patients enrolled in the study. Theanalysis was designed to assess early differences in response betweenloco-regional tumours and metastatic tumours, as classified andobserved by the investigators.